- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07540572
Um Estudo para Investigar a Segurança, Farmacocinética e Eficácia Preliminar da Terapia com IDE574 em Participantes Adultos com Tumores Sólidos Avançados
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: IDEAYA Clinical Trials
- Número de telefone: +1-855-433-224
- E-mail: IDEAYAClinicalTrials@ideayabio.com
Locais de estudo
-
-
California
-
Santa Monica, California, Estados Unidos, 90404-2095
- Ativo, não recrutando
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510-3206
- Recrutamento
- Yale School of Medicine - Cedar Street
-
Investigador principal:
- Patricia LoRusso, MD
-
Contato:
- Karen Seely
- Número de telefone: 203-314-3303
- E-mail: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, Estados Unidos, 33322
- Recrutamento
- Florida Clinical Trials Group
-
Investigador principal:
- Harshad Amin, MD
-
Contato:
- Sandra Perez
- Número de telefone: 772-297-3057
- E-mail: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322-1013
- Recrutamento
- Winship Cancer Institute, Emory University
-
Investigador principal:
- Shipra Gandhi, MD
-
Contato:
- Alejandra Bono
- Número de telefone: 404-778-0954
- E-mail: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110-1010
- Recrutamento
- Washington University - Siteman Cancer Center
-
Investigador principal:
- Faisal Fa'ak, MD
-
Contato:
- Pamela Coe
- Número de telefone: 314-747-7569
- E-mail: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Recrutamento
- START Astera, LLC
-
Investigador principal:
- Bruno Fang, MD
-
Contato:
- Bruno S Fang
- Número de telefone: 732-426-4750
- E-mail: info@startresearch.com
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Recrutamento
- START New York Long Island, LLC
-
Investigador principal:
- Geraldine O'Sullivan Coyne, MD
-
Contato:
- Geraldine O'Sullivan Coyne
- Número de telefone: 363-207-5160
- E-mail: g.osullivancoyne@startresearch.com
-
New York, New York, Estados Unidos, 10032-3729
- Ativo, não recrutando
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- SCRI Oncology Partners - PPDS
-
Investigador principal:
- Sarah Premji, MD
-
Contato:
- Connor Frost
- Número de telefone: 615-478-3475
- E-mail: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, Estados Unidos, 78758
- Recrutamento
- NEXT Texas LLC - Austin
-
Investigador principal:
- Sheena Sahota, MD
-
Contato:
- Heather Watson
- Número de telefone: 737-610-5202
- E-mail: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, Estados Unidos, 75039
- Recrutamento
- NEXT Texas LLC - Dallas
-
Investigador principal:
- Faran Polani, MD
-
Contato:
- Carmen Gonzalez
- Número de telefone: 210-580-9479
- E-mail: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- START Dallas Fort Worth, LLC
-
Investigador principal:
- Henry Xiong, MD
-
Contato:
- Henry Xiong
- Número de telefone: 682-350-3010
- E-mail: info@startresearch.com
-
Houston, Texas, Estados Unidos, 77030-4009
- Recrutamento
- MD Anderson Cancer Center
-
Investigador principal:
- Timothy Yap, MD
-
Contato:
- Desirae Dufner
- Número de telefone: 713-524-3434
- E-mail: DDufner@mdanderson.org
-
Houston, Texas, Estados Unidos, 77054
- Recrutamento
- NEXT Texas LLC - Houston
-
Investigador principal:
- Jennifer Segar, MD
-
Contato:
- Carmen Gonzalez
- Número de telefone: 210-580-9479
- E-mail: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- NEXT Texas LLC - San Antonio
-
Investigador principal:
- David Sommerhalder, MD
-
Contato:
- April Guerra
- Número de telefone: 210-580-9500
- E-mail: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- Start San Antonio, LLC
-
Investigador principal:
- Amita Patnaik, MD
-
Contato:
- Hector Navarro
- Número de telefone: 210-593-5700
- E-mail: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, Estados Unidos, 84119
- Recrutamento
- START Mountain Region, LLC
-
Investigador principal:
- William McKean, MD
-
Contato:
- William B McKean
- Número de telefone: 1 (801) 907-4750
- E-mail: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- NEXT Virginia
-
Investigador principal:
- Mohamad Salkeni, MD
-
Contato:
- Maybelle De La Rosa
- Número de telefone: 703-783-4518
- E-mail: nxtvir_coordinators@nextoncology.com
-
-
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Geórgia, 6000
- Recrutamento
- High Technology Hospital MedCenter Ltd
-
Investigador principal:
- Tamta Makharadze, MD
-
Contato:
- Mamuka Sikharulidze
- Número de telefone: +995 568 999 559
- E-mail: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Geórgia, 114
- Recrutamento
- Pineo Medical Ecosystem
-
Contato:
- Nino Kekenadze
- Número de telefone: +995 593 660 940
- E-mail: Nkekenadze@pineo.ge
-
Investigador principal:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Geórgia, 112
- Ativo, não recrutando
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Geórgia, 144
- Ativo, não recrutando
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Geórgia, 186
- Ativo, não recrutando
- LLC Caucasus Medical Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Experimental: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Experimental: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Prazo: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Prazo: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Prazo: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Prazo: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Prazo: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Prazo: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Prazo: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Prazo: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Prazo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Prazo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Prazo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Prazo: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Prazo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Prazo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Prazo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Prazo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Prazo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Prazo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Prazo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Prazo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Prazo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Prazo: total study duration
|
total study duration
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IDE574-001
- 178299 (Outro identificador: Regulatory Agency Identifier Number (s))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .